# Biohaven Ltd. Common Shares (BHVN) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $15.69, market value $2.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Biohaven Ltd. Common Shares reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 193.7×**. The shares trade at 193.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -21.6%** (5-yr avg -31.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Growth
- **EPS growth (1 yr): 26.1%**. Earnings per share rose 26.1%.

## Financial health
- **Current ratio: 3.18** (quick 3.18). Current assets cover the next year's liabilities 3.18 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Biohaven Ltd. Common Shares does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (15 analysts). 15 analysts cover Biohaven Ltd. Common Shares; the consensus is buy, with an average price target of $21.73 (+39% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -2.4%** (YTD 39.0%, 3-mo 45.3%). The shares are down 2.4% over twelve months including dividends.
- **From 52-week high: -15.5%** (109.8% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.07** (volatility 90%). Beta of 1.07 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BHVN · Page: https://foliofundamentals.com/stocks/bhvn

Not investment advice.